SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients
- PMID: 34878034
- PMCID: PMC8610223
- DOI: 10.6061/clinics/2021/e3548
SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients
Abstract
Objectives: In this preliminary study we investigated cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens in blood samples from 14 recovered coronavirus disease 2019 (COVID-19) patients and compared them to those in samples from 12 uninfected/unvaccinated volunteers.
Methods: Cellular immunity was assessed by intracellular detection of IFN-γ in CD3+ T lymphocytes after stimulation with SARS-CoV-2 spike (S1), nucleocapsid (NC), or receptor-binding domain (RBD) recombinant proteins or overlapping peptide pools covering the sequence of SARS-CoV-2 spike, membrane and nucleocapsid regions. The humoral response was examined by ELISAs and/or chemiluminescence assays for the presence of serum IgG antibodies directed to SARS-CoV-2 proteins.
Results: We observed differences between humoral and cellular immune profiles in response to stimulation with the same proteins. Assays of IgG antibodies directed to SARS-CoV-2 NC, RBD and S1/S2 recombinant proteins were able to differentiate convalescent from uninfected/unvaccinated groups. Cellular immune responses to SARS-CoV-2 protein stimuli did not exhibit a specific response, as T cells from both individuals with no history of contact with SARS-CoV-2 and from recovered donors were able to produce IFN-γ.
Conclusions: Determination of the cellular immune response to stimulation with a pool of SARS-CoV-2 peptides but not with SARS-CoV-2 proteins is able to distinguish convalescent individuals from unexposed individuals. Regarding the humoral immune response, the screening for serum IgG antibodies directed to SARS-CoV-2 proteins has been shown to be specific for the response of recovered individuals.
Conflict of interest statement
No potential conflict of interest was reported.
Figures







Similar articles
-
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021. Front Immunol. 2021. PMID: 35003131 Free PMC article.
-
Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19-convalescent individuals.J Allergy Clin Immunol. 2022 Apr;149(4):1225-1241. doi: 10.1016/j.jaci.2022.01.005. Epub 2022 Jan 21. J Allergy Clin Immunol. 2022. PMID: 35074422 Free PMC article.
-
Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.Front Immunol. 2021 Dec 17;12:797919. doi: 10.3389/fimmu.2021.797919. eCollection 2021. Front Immunol. 2021. PMID: 34975908 Free PMC article.
-
Severe Acute Respiratory Syndrome Coronavirus 2 Antigens as Targets of Antibody Responses.Clin Lab Med. 2022 Mar;42(1):97-109. doi: 10.1016/j.cll.2021.10.002. Epub 2021 Nov 3. Clin Lab Med. 2022. PMID: 35153051 Free PMC article. Review.
-
Suboptimal Humoral Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Viral Variant Generation.Clin Lab Med. 2022 Mar;42(1):75-84. doi: 10.1016/j.cll.2021.10.001. Epub 2021 Nov 3. Clin Lab Med. 2022. PMID: 35153049 Free PMC article. Review.
Cited by
-
Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19.Sci Rep. 2022 Jun 16;12(1):10125. doi: 10.1038/s41598-022-14283-x. Sci Rep. 2022. PMID: 35710573 Free PMC article.
-
Convalescent Adaptive Immunity Is Highly Heterogenous after SARS-CoV-2 Infection.J Clin Med. 2023 Nov 16;12(22):7136. doi: 10.3390/jcm12227136. J Clin Med. 2023. PMID: 38002748 Free PMC article.
-
SARS-CoV-2 Activated Peripheral Blood Mononuclear Cells (PBMCs) Do Not Provoke Adverse Effects in Trophoblast Spheroids.Am J Reprod Immunol. 2025 Jan;93(1):e70039. doi: 10.1111/aji.70039. Am J Reprod Immunol. 2025. PMID: 39776066 Free PMC article.
-
Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.Immun Inflamm Dis. 2024 Apr;12(4):e1250. doi: 10.1002/iid3.1250. Immun Inflamm Dis. 2024. PMID: 38661242 Free PMC article. Review.
-
SARS-CoV-2 infectivity and antigenic evasion: spotlight on isolated Omicron sub-lineages.Front Med (Lausanne). 2024 Aug 29;11:1414331. doi: 10.3389/fmed.2024.1414331. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39267969 Free PMC article.
References
-
- Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med. 2020;28(2):174–84. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous